Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes

Clinical and Experimental Nephrology

Volumn 6, Issue 3, 2002, Pages 135-139

  Nakamura, T ^a   Ushiyama, C ^a   Osada, S ^b   Takahashi, Y ^c   Shimada, N ^d   Ebihara, I ^d   Koide, H ^d  

^a Misato Junshin General Hospital   (Japan)

^b NATIONAL REHABILITATION CENTER FOR PERSONS WITH DISABILITIES   (Japan)

^c Mizue Kidney Clinic   (Japan)

^d KOTO HOSPITAL   (Japan)

Author keywords

Angiotensin; Candesartan cilexetil; Endothelin; Microalbuminuria; Trandolapril

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; GLIBENCLAMIDE; ORAL ANTIDIABETIC AGENT; TRANDOLAPRIL; VOGLIBOSE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY BLOOD FLOW; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 0036710336     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101570200023     Document Type: Article

References (26)

1. Okonogi H, Nishimura M, Utsunomiya Y, Hamaguchi K, Tsuchida H, Miura Y, et al. Urinary type IV collagen excretion reflects renal morphology alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol 2001;55:357-64.
2. Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetes. Nephrol Dial Transplant 2001;16(Suppl 1):85-9.
3. Buter H, Navis G, Dullaart RPF, de Zeeuw D, de Jong PE. Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 2001;16:771-5.
4. Kuriyama S, Tomonari H, Abe A, Imasawa T, Hosoya T. Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy. Nephron 2000;86:529-30.
5. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
6. Report of the Expert Committee on the Diagnosis and classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
7. Cecioni I, Modesti PA, Poggesti L, Rocchi F, Rega L, Neri Semeri GG. Endothelin-1 urinary excretion, but not endothelin-1 plasma concentration, is increased in renovascular hypertension. J Lab Clin Med 1999;134:386-91.
8. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetes with early nephropathy. Kidney Int 2000;58:762-9.
9. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin-dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
10. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996;156:286-9.
11. Bojestig M, karlberg BE, Lindstrom T, Nystrom FH. Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care 2001;24:919-24.
12. Wheeldon VM, On behalf of the MARVAL Investigators. Microalbuminuria reduction with valsartan. Presented at the American Society of Hypertension (ASH) 2001; May 15-19, 2001, San Francisco, USA.
13. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001;37:890-9.
14. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol 2000;20:373-9.
15. Lee YJ, Shin SJ, Tsai JH. Increased urinary endothelin-1 like immunoreactivity in NIDDM patients with albuminuria. Diabetes Care 1994;17:263-6.
16. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and/or urinary albumin excretion in diabetic patients. J Diabetes Complications 2000;14:250-4.
17. Fukui M, Nakamura T, Ebihara I, Osada S, Tomino Y, Masaki T, et al. Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med 1993;122:149-56.
18. Fukui M, Nakamura T, Ebihara I, Makita Y, Osada S, Tomino Y, et al. Effects of enalapril on endothelin-1 and growth factors gene expression in diabetic rat glomeruli. J Lab Clin Med 1994;123:763-8.
19. Yao J, Morioka T, Li B, Oite T. Endothelin is a potent inhibitor of matrix metalloproteinase-2 secretion and activation in rat mesangial cells. Am J Physiol Renal Physiol 2001;280:F628-35.
20. Hocher B, Liefeldt L, Thone-Reineke C, Orzekowski HD, Distler A, Bauer C, et al. Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 1996;28:196-201.
21. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, et al. Endothelin-1 transgenic mice develop renal cysts, interstitial fibrosis and glomerulosclerosis but not hypertension. J Clin Invest 1997;99:1380-9.
22. Cohen Mp, Lautenslager GT, Shearman CW. Increased collagen IV excretion in diabetes. Diabetes Care 2001;24:914-8.
23. Hocher B, Schwarz A, Reinbacher D, Jacobi J, Lun A, Priem F, et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001;87:161-9.
24. Hara M, Kobayashi N, Nakao S, Mori Y, Tsubokou Y, Matsuoka H. Effects of TCV-116 on endothelin-1 and PDGF-A chain expression in angiotensin II-induced hypertensive rats. Hypertens Res 2001;24:55-64.
25. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992;19:753-7.
26. Firth JD, Schricker K, Ratcliffe PJ, Kurtz A. Expression of endothelins 1 and 3 in the rat kidney. Am J Physiol 1995;269:F522-8.